3H2 CAR T cells

3H2 CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target glioblastoma (GBM). Developed by researchers at Washington University School of Medicine, these cells utilize a T-cell receptor (TCR)-like antibody clone (3H2) that specifically recognizes a telomerase reverse transcriptase (TERT)-derived antigen presented by the HLA-A*02:01 MHC molecule. While the original 3H2 construct required exogenous TERT antigen for cytotoxicity, an optimized version with flipped heavy and light chains (3H2F) demonstrated effective in vitro killing of GBM cells without exogenous peptide. This approach aims to overcome the immune-evasive nature of GBM by targeting a widely expressed tumor-associated antigen through a TCR-like recognition mechanism.

Other names

TERT-specific TCR-like antibody CAR T cells3H2 CAR-T